Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92

被引:115
作者
Harms, DO [1 ]
Janka-Schaub, GE [1 ]
机构
[1] Childrens Univ Hosp, Dept Hematol & Oncol, D-20246 Hamburg, Germany
关键词
childhood; lymphoblastic leukemia; outcome; CNS control;
D O I
10.1038/sj.leu.2401974
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The German Go-operative Study Group COALL far treatment of acute lymphoblastic leukemia (ALL) in childhood started the first trial in 1980. This report gives an overview of the long-term results of the four consecutive studies COALL-82, COALL-85, COALL-89 and COALL-92. Besides improvement in long-term survival major objectives were reduction of treatment-related toxicity by transferring asparaginase (ASP) from induction therapy to intensive phase and omitting CNS irradiation by stepwise increase of the initial white blood count (WBC) up to 50 x 10(9)/1 (exception T-ALL) as criterion for irradiation. In study COALL-85 in high risk patients slow vs rapid rotational treatment was randomized. In study COALL-92 initial response to daunorubicin (DNR) as a l-h vs 24-h infusion and its prognostic value was investigated. Furthermore, g-mercaptopurine (6-MP) and B-thioguanine (6-TG) were randomized in maintenance treatment. In total, 1191 eligible patients were enrolled. Induction treatment without ASP has been shown to be as effective and less hazardous than the former four-drug induction. CNS control could be obtained in most without cranial irradiation (CNS relapse-free survival >95%). The leukemic cell kill with a 24-h DNR infusion was equivalent to that of a l-h infusion. DNR response was of less prognostic significance than prednisone response. The rapid rotation regimen failed to improve outcome as well as 6-TG in maintenance treatment. However, intensification of systemic treatment resulted in an increase in overall event-free survival (EFS) to approximately 80% which is comparable to other groups.
引用
收藏
页码:2234 / 2239
页数:6
相关论文
共 13 条
  • [1] COX DR, 1972, J R STAT SOC B, V34, P187
  • [2] Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine
    Erb, N
    Harms, DO
    Janka-Schaub, G
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (04) : 266 - 272
  • [3] HARMS D, 1994, MED PEDIATR ONCOL, V23, P197
  • [4] Janka G E, 1987, Haematol Blood Transfus, V30, P456
  • [5] ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDHOOD - THE COALL THERAPY STUDIES
    JANKA, GE
    WINKLER, K
    JURGENS, H
    GOBEL, U
    GUTJAHR, P
    SPAAR, HJ
    [J]. KLINISCHE PADIATRIE, 1986, 198 (03): : 171 - 177
  • [6] JANKA GE, 1999, MED PEDIATR ONCOL, V33, P217
  • [7] JUERGENS H, 1992, HAEMATOL BLOODTRANSF, V34, P338
  • [8] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [9] THE INVIVO RESPONSE ON CORTICOSTEROID-THERAPY AS AN ADDITIONAL PROGNOSTIC FACTOR IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA (THERAPY STUDY ALL-BFM 83)
    RIEHM, H
    REITER, A
    SCHRAPPE, M
    BERTHOLD, F
    DOPFER, R
    GEREIN, V
    LUDWIG, R
    RITTER, J
    STOLLMANN, B
    HENZE, G
    [J]. KLINISCHE PADIATRIE, 1987, 199 (03): : 151 - 160
  • [10] SCHAUB GEJ, 1988, KLIN PADIATR, V200, P171